D3.207 - Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece

Allergen Immunotherapy (AIT) is a targeted treatment for allergic conditions caused by aeroallergens. The aim of the present study is to record and analyze data regarding the symptom profile and sensitizations of patients undergoing subcutaneous AIT.

We conducted a review of the medical records of all 250 patients undergoing subcutaneous AIT during the period from January to February 2025 at the Immunotherapy Clinic of the Allergy Department of Laiko Hospital.

A total of 210 patients were finally included, who underwent immunotherapy for the first time at our department. The median age was 37 (14-80) years and 115 were females). The median age at onset of respiratory symptoms was 17 years. The vast majority of patients (98.6%) reported rhinitis, of whom 38.2% also reported asthma. Only seasonal symptoms were reported by 125 patients (59.5%). The most frequent sensitization was to parietaria (65.2%), followed by grasses (59%), olea (53.8%), house dust mites (44.3%), cypress (42.4%), and animal epithelia (41.9%). Combined sensitization to parietaria, olea, and grasses was observed in 62 patients (29.5%), approximately half of whom were also sensitized to cypress. Notably, sensitization to ambrosia artemisiifolia was observed in 23.3% of patients. Monosensitization was most frequent for parietaria and mites, in 10 and 9 patients, respectively. No monosensitization to cat or to dog was observed; however, one patient exhibited monosensitization to animal epithelia (both cat and dog).

The frequency of asthma in patients undergoing immunotherapy for allergic rhinitis is similar to that reported in the international literature. Sensitization to spring aeroallergens predominates, with parietaria being the most common, while sensitization to Ambrosia appears to be higher compared to the past. Monosensitizations, both to pollen and to other aeroallergens, are infrequent. The symptomatology of patients undergoing AIT aligns with international data; however, sensitization to ambrosia artemisiifolia is increasingly observed in contemporary Greece.